|
|
Volumn 8, Issue 4, 2003, Pages 303-306
|
|
FDA drug approval summary: Gefitinib (ZD1839) (Iressa®) tablets
a
|
|
Author keywords
Gefitinib; Iressa ; Non small cell lung cancer, metastatic; Third line treatment
|
|
Indexed keywords
CARBOPLATIN;
CISPLATIN;
DOCETAXEL;
GEFITINIB;
GEMCITABINE;
PACLITAXEL;
PLACEBO;
PLATINUM;
PROTEIN TYROSINE KINASE INHIBITOR;
ACNE;
ADULT;
AGED;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DOUBLE BLIND PROCEDURE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG SAFETY;
DRY SKIN;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
INTERSTITIAL LUNG DISEASE;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
RASH;
REVIEW;
SEX DIFFERENCE;
SMOKING;
TABLET;
VOMITING;
ADMINISTRATION, ORAL;
ADOLESCENT;
ADULT;
AGED;
CARCINOMA, NON-SMALL-CELL LUNG;
CONFIDENCE INTERVALS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
DRUG APPROVAL;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
LUNG NEOPLASMS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASM STAGING;
PROBABILITY;
QUINAZOLINES;
REFERENCE VALUES;
SURVIVAL ANALYSIS;
TABLETS;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0043210670
PISSN: 10837159
EISSN: None
Source Type: Journal
DOI: 10.1634/theoncologist.8-4-303 Document Type: Review |
|
Times cited : (546)
|
|
References (0)
|
